Biochem Pharma
Executive Summary
$150 mil. profit expected in fiscal year 1999 as the company completes divestiture of its diagnostics program and aggressively expands its anti-infective and oncology pipeline, Biochem Pharma CEO Francesco Bellini, PhD, told analysts Jan. 11. Company earnings for FY 98 are $110 mil., with $800 mil. in lamivudine sales (Epivir and Epivir HBV). The company believes that the September approval of DuPont's Sustiva non-nucleoside analog reverse transcriptase inhibitor will help boost Epivir sales in 1999 as part of an AZT/3TC/Sustiva combination therapy